These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
    Author: Hershman MJ, Habib NA, Kelly SB, Beynon J, Williamson RC, Davies PW, Wood CB.
    Journal: Eur J Surg Oncol; 1988 Oct; 14(5):413-5. PubMed ID: 3181445.
    Abstract:
    The role of the tumour marker CA-50 has been studied in the differential diagnosis of benign and malignant breast disease. Serum levels of CA-50 were determined by radioimmunoassay using a level of 17 units/ml as a cut-off. All 50 normal subjects and 22 of 24 patients (92%) with benign breast disease had CA-50 levels below 17 units/ml. By contrast, 15 of 36 patients (42%) with breast carcinoma had serum CA-50 levels above 17 units/ml (P less than 0.001). There was no clear correlation with tumour stage. The data suggest that CA-50 levels may help to differentiate benign and malignant diseases of the breast.
    [Abstract] [Full Text] [Related] [New Search]